Century Therapeutics is developing novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies.
Our commitment to developing accessible cell therapies provides an unparalleled opportunity to advance the course of cancer care.
We harness the power of adult stem cells to
develop curative therapies for cancer.
Our dedicated team is developing novel allogeneic living cell products for oncology that overcome the limitations of first-generation cell therapies.
We want to change cancer therapy for good.
For the better, for everyone.
BOARD OF DIRECTORS
Leaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences—targeting the breakthroughs that could fundamentally change the world for the better.
FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSC) utilized in drug discovery and cell therapies. The pre-clinical stage company is using its expertise in iPSC technologies to develop a robust cell therapeutics pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, congestive heart failure, and immuno-oncology. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the company’s inventoried iCell® products are available in almost any cell type and they are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell services and cell banking. FCDI’s goal is to leverage the vast utility of iPSC to advance human health and improve the quality of life for patients around the world.
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With USD3 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and clinical expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 70 Versant companies have achieved successful acquisitions or IPOs.